IL154012A0 - Hydrogel-driven drug dosage form - Google Patents

Hydrogel-driven drug dosage form

Info

Publication number
IL154012A0
IL154012A0 IL15401201A IL15401201A IL154012A0 IL 154012 A0 IL154012 A0 IL 154012A0 IL 15401201 A IL15401201 A IL 15401201A IL 15401201 A IL15401201 A IL 15401201A IL 154012 A0 IL154012 A0 IL 154012A0
Authority
IL
Israel
Prior art keywords
hydrogel
dosage form
drug dosage
driven drug
driven
Prior art date
Application number
IL15401201A
Other languages
English (en)
Original Assignee
Pfizer Prod Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc
Publication of IL154012A0 publication Critical patent/IL154012A0/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
    • A61K9/0004—Osmotic delivery systems; Sustained release driven by osmosis, thermal energy or gas
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
IL15401201A 2000-08-09 2001-08-03 Hydrogel-driven drug dosage form IL154012A0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US22419900P 2000-08-09 2000-08-09
PCT/IB2001/001390 WO2002011702A2 (en) 2000-08-09 2001-08-03 Hydrogel-driven drug dosage form

Publications (1)

Publication Number Publication Date
IL154012A0 true IL154012A0 (en) 2003-07-31

Family

ID=22839665

Family Applications (1)

Application Number Title Priority Date Filing Date
IL15401201A IL154012A0 (en) 2000-08-09 2001-08-03 Hydrogel-driven drug dosage form

Country Status (30)

Country Link
US (2) US20030086972A1 (hu)
EP (1) EP1326587A2 (hu)
JP (1) JP2004505907A (hu)
KR (1) KR20030024844A (hu)
CN (1) CN1461212A (hu)
AP (1) AP2001002237A0 (hu)
AU (1) AU2002229141A1 (hu)
BG (1) BG107538A (hu)
BR (1) BR0113067A (hu)
CA (1) CA2418907A1 (hu)
DO (1) DOP2001000229A (hu)
EA (1) EA200300081A1 (hu)
EC (1) ECSP034455A (hu)
EE (1) EE200300055A (hu)
GT (1) GT200100161A (hu)
HR (1) HRP20030082A2 (hu)
HU (1) HUP0300722A2 (hu)
IL (1) IL154012A0 (hu)
IS (1) IS6686A (hu)
MA (1) MA26939A1 (hu)
MX (1) MXPA03001209A (hu)
NO (1) NO20030627L (hu)
OA (1) OA12365A (hu)
PA (1) PA8524901A1 (hu)
PE (1) PE20020307A1 (hu)
PL (1) PL360658A1 (hu)
SV (1) SV2002000586A (hu)
TN (1) TNSN01123A1 (hu)
UY (1) UY26876A1 (hu)
WO (1) WO2002011702A2 (hu)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0957073A1 (en) 1998-05-12 1999-11-17 Schwarz Pharma Ag Novel derivatives of 3,3-diphenylpropylamines
MXPA02006328A (es) * 1999-12-23 2002-12-13 Pfizer Prod Inc Forma de dosificacion de farmacos accionada por un hidrogel.
AR030557A1 (es) 2000-04-14 2003-08-27 Jagotec Ag Una tableta en multicapa de liberacion controlada y metodo de tratamiento
WO2002055009A1 (en) 2001-01-12 2002-07-18 Sun Pharmaceutical Industries Limited Spaced drug delivery system
BR0212950A (pt) 2001-09-28 2004-10-26 Mcneil Ppc Inc Formas de dosagens compósitas tendo uma porção inserida
WO2003096968A2 (en) * 2002-05-15 2003-11-27 Sun Pharmaceutical Industries Limited Oral osmotic controlled drug delivery system
US8084058B2 (en) 2002-09-20 2011-12-27 Watson Pharmaceuticals, Inc. Pharmaceutical formulation containing a biguanide and a thiazolidinedione derivative
US7959946B2 (en) 2002-09-20 2011-06-14 Watson Pharmaceuticals, Inc. Pharmaceutical formulation containing a biguanide and a thiazolidinedione derivative
KR101363679B1 (ko) * 2002-09-20 2014-02-14 안드렉스 랩스 엘엘씨 약제학적 정제
US9060941B2 (en) 2002-09-20 2015-06-23 Actavis, Inc. Pharmaceutical formulation containing a biguanide and a thiazolidinedione derivative
US7785627B2 (en) 2002-09-20 2010-08-31 Watson Pharmaceuticals, Inc. Pharmaceutical formulation containing a biguanide and a thiazolidinedione derivative
US7807197B2 (en) 2002-09-28 2010-10-05 Mcneil-Ppc, Inc. Composite dosage forms having an inlaid portion
WO2004028511A1 (en) * 2002-09-28 2004-04-08 Mcneil-Ppc, Inc. Solid dosage form comprising ketoprofen
FR2850576B1 (fr) * 2003-02-05 2007-03-23 Ethypharm Sa Composition comprenant un melange de principes actifs, et procede de preparation
US20060210633A1 (en) * 2003-04-03 2006-09-21 Sun Pharmaceutical Industries Limited Programmed drug delivery system
DE10315917A1 (de) * 2003-04-08 2004-11-18 Schwarz Pharma Ag Hochreine Basen von 3,3-Diphenylpropylaminmonoestern
AR040157A1 (es) * 2003-06-06 2005-03-16 Rodriguez Julio Cesar Una formulacion en microgranulos para administracion oral en suspension acuosa
CA2534371A1 (en) * 2003-08-04 2005-02-10 Pfizer Products Inc. Dosage forms providing controlled release of cholesteryl ester transfer protein inhibitors and immediate release of hmg-coa reductase inhibitors
US7879354B2 (en) 2004-01-13 2011-02-01 Mcneil-Ppc, Inc. Rapidly disintegrating gelatinous coated tablets
US8067029B2 (en) 2004-01-13 2011-11-29 Mcneil-Ppc, Inc. Rapidly disintegrating gelatinous coated tablets
CA2601762A1 (en) * 2005-02-03 2006-08-10 Pfizer Products Inc. Dosage forms providing controlled and immediate release of cholesteryl ester transfer protein inhibitors and immediate release of hmg-coa reductase inhibitors
US20060228413A1 (en) * 2005-02-28 2006-10-12 Penwest Pharmaceuticals Co. Controlled release venlafaxine formulations
JP5020931B2 (ja) * 2005-03-14 2012-09-05 サン・ファーマ・アドバンスド・リサーチ・カンパニー・リミテッド 経口薬剤送達システム
CA2600736A1 (en) * 2005-03-16 2006-09-21 Dr. Reddy's Laboratories Ltd. Delivery system for multiple drugs
US8673352B2 (en) 2005-04-15 2014-03-18 Mcneil-Ppc, Inc. Modified release dosage form
CN100448433C (zh) * 2005-09-21 2009-01-07 广州贝氏药业有限公司 一种克拉霉素肠溶药物组合物
WO2007124372A2 (en) * 2006-04-20 2007-11-01 Transport Pharmaceuticals, Inc. Pharmaceutical formulations for iontophoretic methotrexate delivery
SA07280459B1 (ar) * 2006-08-25 2011-07-20 بيورديو فارما إل. بي. أشكال جرعة صيدلانية للتناول عن طريق الفم مقاومة للعبث تشتمل على مسكن شبه أفيوني
KR20080076382A (ko) * 2007-02-15 2008-08-20 (주)아모레퍼시픽 실로스타졸의 제어방출 제제 및 그 제조방법
CA2715584A1 (en) * 2008-02-15 2009-10-08 Sun Pharma Advanced Research Company Ltd. Oral controlled release tablet
MX2012005264A (es) * 2009-11-09 2012-07-03 Capsugel Belgium Nv Portador de suministro.
JP5390014B2 (ja) 2010-03-19 2014-01-15 第一三共株式会社 抗凝固剤の溶出改善方法
ES2673182T3 (es) * 2011-08-10 2018-06-20 Daiichi Sankyo Company, Limited Composición farmacéutica que contiene un derivado de diamina
US9918937B2 (en) * 2013-01-30 2018-03-20 Daewoong Co., Ltd. Pharmaceutical composition for protecting wounds, providing hemostasis, or preventing adhesion in the gastrointestinal tract
MA41868A (fr) * 2015-04-01 2018-02-06 Spectrum Brands Inc Pastille retard et procédés s'y rapportant
EP3761961A4 (en) 2018-03-07 2022-01-05 Andrew Xian Chen AQUEOUS FORMULATIONS FOR INSOLUBLE DRUGS
TW202313006A (zh) * 2021-05-28 2023-04-01 美商安進公司 阿普斯特配製物
CN113600179B (zh) * 2021-09-16 2023-07-04 山东博霖环保科技发展有限公司 一种脱硝催化剂及其制备方法
JPWO2023063381A1 (hu) * 2021-10-14 2023-04-20

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1025765B (it) * 1974-11-18 1978-08-30 Gastaldi Francesco Essiccatore perfezionato a spruzzo
US4187617A (en) * 1978-12-18 1980-02-12 Becker James J Jr Spray dryer
US4327725A (en) * 1980-11-25 1982-05-04 Alza Corporation Osmotic device with hydrogel driving member
US4449983A (en) * 1982-03-22 1984-05-22 Alza Corporation Simultaneous delivery of two drugs from unit delivery device
US4612008A (en) * 1983-05-11 1986-09-16 Alza Corporation Osmotic device with dual thermodynamic activity
US4624848A (en) * 1984-05-10 1986-11-25 Ciba-Geigy Corporation Active agent containing hydrogel devices wherein the active agent concentration profile contains a sigmoidal concentration gradient for improved constant release, their manufacture and use
US4851232A (en) * 1987-02-13 1989-07-25 Alza Corporation Drug delivery system with means for obtaining desirable in vivo release rate pattern
GB8820353D0 (en) * 1988-08-26 1988-09-28 Staniforth J N Controlled release tablet
US5612059A (en) * 1988-08-30 1997-03-18 Pfizer Inc. Use of asymmetric membranes in delivery devices
US5096716A (en) * 1988-09-01 1992-03-17 Alza Corporation Dosage form for administering calcium antagonist nicardipine
IL92966A (en) * 1989-01-12 1995-07-31 Pfizer Hydrogel-operated release devices
US5030452A (en) * 1989-01-12 1991-07-09 Pfizer Inc. Dispensing devices powered by lyotropic liquid crystals
US5120548A (en) * 1989-11-07 1992-06-09 Merck & Co., Inc. Swelling modulated polymeric drug delivery device
JPH05178763A (ja) * 1991-02-19 1993-07-20 Nippon Saafuakutanto Kogyo Kk 難溶解性薬物溶解剤組成物
MX9605419A (es) * 1994-05-06 1997-12-31 Pfizer Formas de dosificacion de liberacion controlada de azitromicina.
US5654005A (en) * 1995-06-07 1997-08-05 Andrx Pharmaceuticals, Inc. Controlled release formulation having a preformed passageway
TW487582B (en) * 1995-08-11 2002-05-21 Nissan Chemical Ind Ltd Method for converting sparingly water-soluble medical substance to amorphous state
EP0999829A1 (en) * 1997-07-01 2000-05-17 Pfizer Products Inc. Solubilized sertraline compositions
NZ501251A (en) * 1997-07-01 2001-09-28 Pfizer Sertraline salts and sustained-release dosage forms of sertraline
DE19747261A1 (de) * 1997-10-25 1999-04-29 Bayer Ag Osmotisches Arzneimittelfreisetzungssystem
US6037346A (en) * 1997-10-28 2000-03-14 Vivus, Inc. Local administration of phosphodiesterase inhibitors for the treatment of erectile dysfunction
CN1184962C (zh) * 1998-10-13 2005-01-19 辉瑞产品公司 口服舍曲林浓缩物
EP1027888B1 (en) * 1999-02-10 2009-06-10 Pfizer Products Inc. Osmotic system for delivery of solid amorphous dispersions of drugs
US6500459B1 (en) * 1999-07-21 2002-12-31 Harinderpal Chhabra Controlled onset and sustained release dosage forms and the preparation thereof
AR028253A1 (es) * 2000-03-16 2003-04-30 Pfizer Prod Inc Inhibidores de la glucogeno fosforilasa
JP2006510655A (ja) * 2002-12-11 2006-03-30 ファイザー・プロダクツ・インク 高脂肪環境への活性物質の制御放出

Also Published As

Publication number Publication date
PE20020307A1 (es) 2002-04-23
HRP20030082A2 (en) 2003-04-30
DOP2001000229A (es) 2002-09-30
PL360658A1 (en) 2004-09-20
MA26939A1 (fr) 2004-12-20
UY26876A1 (es) 2002-03-22
CN1461212A (zh) 2003-12-10
EP1326587A2 (en) 2003-07-16
BR0113067A (pt) 2003-07-01
US20040052845A1 (en) 2004-03-18
WO2002011702A2 (en) 2002-02-14
NO20030627L (no) 2003-04-08
AP2001002237A0 (en) 2001-09-30
WO2002011702A3 (en) 2002-11-28
EE200300055A (et) 2004-12-15
EA200300081A1 (ru) 2003-08-28
AU2002229141A1 (en) 2002-02-18
MXPA03001209A (es) 2003-06-30
IS6686A (is) 2003-01-16
KR20030024844A (ko) 2003-03-26
JP2004505907A (ja) 2004-02-26
BG107538A (bg) 2003-11-28
HUP0300722A2 (hu) 2003-11-28
SV2002000586A (es) 2002-10-24
PA8524901A1 (es) 2002-04-25
OA12365A (en) 2006-05-16
CA2418907A1 (en) 2002-02-14
TNSN01123A1 (fr) 2005-11-10
ECSP034455A (es) 2003-03-10
US20030086972A1 (en) 2003-05-08
NO20030627D0 (no) 2003-02-07
GT200100161A (es) 2002-03-22

Similar Documents

Publication Publication Date Title
IL154012A0 (en) Hydrogel-driven drug dosage form
IL149224A0 (en) Hydrogen-driven drug dosage form
GB0117618D0 (en) Pharmaceutical dosage form
IL150657A0 (en) Multi-step drug dosage forms
GB0117619D0 (en) Pharmaceutical dosage form
GB0020691D0 (en) Pharmaceutical combination
GB0031084D0 (en) Pharmaceutical compounds
GB0012291D0 (en) Pharmaceutical combination
GB0019272D0 (en) Pharmaceutical compounds
GB0024318D0 (en) Pharmaceutical compounds
GB0021487D0 (en) Pharmaceutical
GB0005366D0 (en) Pharmaceutical compounds
GB0012293D0 (en) Pharmaceutical combination
IL134581A0 (en) Pharmaceutical dosage form
IL128582A0 (en) Pharmaceutical dosage form
PL341178A1 (en) Oral pharmaceutical dosage forms
GB0009080D0 (en) Drug delivery
GB0004119D0 (en) Drug delivery
GB0017141D0 (en) Pharmaceutical
GB0004021D0 (en) Pharmaceutical
GB0013001D0 (en) Pharmaceutical
GB0016563D0 (en) Pharmaceutical
GB0004020D0 (en) Pharmaceutical
GB0028565D0 (en) Pharmaceutical use
GB0017092D0 (en) Medicament